{
    "Trade/Device Name(s)": [
        "Creatinine2"
    ],
    "Submitter Information": "Abbott Ireland Diagnostics Division",
    "510(k) Number": "K210452",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083809"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGX"
    ],
    "Summary Letter Date": "December 6, 2021",
    "Summary Letter Received Date": "December 8, 2021",
    "Submission Date": "December 6, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1225"
    ],
    "Regulation Name(s)": [
        "Creatinine test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Creatinine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Serum separator tube",
        "Dipotassium EDTA tube",
        "Lithium heparin tube",
        "Glass lithium heparin tube",
        "Plastic lithium heparin tube",
        "Sodium heparin tube",
        "Lithium heparin separator tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT c System"
    ],
    "Method(s)/Technology(ies)": [
        "Kinetic Alkaline Picrate",
        "Automated clinical chemistry assay"
    ],
    "Methodologies": [
        "Kinetic Alkaline Picrate"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Creatinine2 assay for quantitative measurement of creatinine in serum, plasma, or urine using kinetic alkaline picrate methodology on the ARCHITECT c System.",
    "Indications for Use Summary": "Quantitative determination of creatinine in human serum, plasma, or urine on the ARCHITECT c System, as an aid in diagnosis and treatment of renal diseases, monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.",
    "fda_folder": "Clinical Chemistry"
}